GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carmell Corp (NAS:CTCX) » Definitions » Earnings Yield (Joel Greenblatt) %

Carmell (Carmell) Earnings Yield (Joel Greenblatt) % : -17.57% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Carmell Earnings Yield (Joel Greenblatt) %?

Carmell's Enterprise Value for the quarter that ended in Dec. 2023 was $87.20 Mil. Carmell's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.88 Mil. Carmell's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -17.57%.

The historical rank and industry rank for Carmell's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

CTCX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -51.97   Med: -25.32   Max: -14.76
Current: -21.23

During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Carmell was -14.76%. The lowest was -51.97%. And the median was -25.32%.

CTCX's Earnings Yield (Joel Greenblatt) % is ranked worse than
56.79% of 1414 companies
in the Biotechnology industry
Industry Median: -15.29 vs CTCX: -21.23

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Carmell's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Carmell Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Carmell's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell Earnings Yield (Joel Greenblatt) % Chart

Carmell Annual Data
Trend Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - -17.57

Carmell Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial - - - -17.70 -17.57

Competitive Comparison of Carmell's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Carmell's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carmell's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carmell's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Carmell's Earnings Yield (Joel Greenblatt) % falls into.



Carmell Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Carmells Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-15.316/87.200186
=-17.56 %

Carmell's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.88 Mil.



Carmell  (NAS:CTCX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Carmell Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Carmell's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Carmell (Carmell) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carmell Corp (NAS:CTCX) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036